This trial is unknown status.

Condition cocaine-related disorders
Treatment gbr 12909
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date August 2002
Trial size 24 participants
Trial identifier NCT00051896, NIDA-CPU-0002-1


The purpose of this study is to assess the potential interactions between iv cocaine and GBR 12909.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Masking double-blind
Primary purpose treatment

Primary Outcomes

Pharmacokinetic parameter comparison
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Must understand study procedures and provide written informed consent - For additional inclusion criteria information, please contact study site for more information. Exclusion Criteria: - Please contact study site for more information.

Additional Information

Official title Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers
Principal investigator Louis Cantilena, M.D.
Description This is a single dose with escalation, double-blind, placebo-controlled inpatient study in which 24 cocaine experienced volunteers that meet protocol eligibility criteria during a 30 day screen period will be randomized into three dose groups.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).